(Albany, USA) DelveInsight’s Epilepsy Pipeline Insight 2023 report offers exhaustive global coverage of available, marketed, and pipeline therapies under different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Epilepsy pipeline domain.
To know more in detail about Epilepsy Pipeline report, click here: Epilepsy Pipeline Insight
Some of the essential takeaways from the Epilepsy Pipeline report:
- DelveInsight’s Epilepsy Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies.
- Major pharmaceutical companies are developing potential drug candidates to improve the Epilepsy treatment scenario, such as Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
- Key Epilepsy pipeline therapies such as OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others are under investigation in different phases of clinical trials.
- In January 2021, Addex Therapeutics announced that its partner Janssen Pharmaceuticals had received FDA’s Investigational New Drug (IND) approval to begin a Phase IIa proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with Epilepsy.
- In October 2020, PTC Therapeutics announced the initiation of a registration-directed Phase II/III clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial Epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease.
Request for Epilepsy sample report to learn more about trends in specific geographies @ Epilepsy Emerging Therapies and Forecast: Epilepsy Clinical Trials Assessment
The Epilepsy pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Epilepsy products, comprehensive assessment of driving and restraining factors, and opportunities as well as risks in the Epilepsy pipeline landscape.
Epilepsy Overview
Epilepsy is a chronic neurological disorder characterized by frequent and recurring seizures leading to unusual behaviour. The primary cause of Epilepsy is not clear, but it is noted that any change in the nerve cells, neurons, and the brain resulting in abnormal signals can be the possible reason.
The most common symptom of Epilepsy includes seizures; however, additional symptoms like convulsion without fever, low consciousness, less awareness, loss of taste, smell, sight, hearing, etc., can also be present.
For further information about Epilepsy treatment and pipeline therapies, visit @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight
Epilepsy Pipeline Drugs
- OPC-214870: Otsuka Pharmaceutical Co. Ltd
- CT-010: Cerebral Therapeutics LLC
- Ganaxolone: Marinus Pharmaceuticals
- XEN496: Xenon Pharmaceuticals
- Vatiquinone: PTC Therapeutics
- E-2730: Eisai
- NBI 827104: Neurocrine Biosciences
Epilepsy Therapeutics Assessment
The Epilepsy Pipeline report proffers an integral view of the Epilepsy emerging novel therapies segregated by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.
By Product Type
• Mono
• Combination
• Mono/Combination
By Stage
• Discovery
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
Dive deep into rich insights of Epilepsy novel and emerging drugs and their analysis @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight
By Route of Administration
• Subcutaneous
• Intravenous
• Oral
• Intraventricular
• Inhalation
By Molecule Type
• Gene therapy
• Stem cell therapy
• Small molecules
• Pyridines
By Mechanism of Action
• 4-aminobutyrate transaminase inhibitors
• GABA A receptor agonists
• KCNQ potassium channel agonists
• NQO1 modulators
• Serotonin receptor agonists
• T type calcium channel antagonists
By Targets
• GABA A receptor
• KCNQ potassium channel
• Serotonin receptor
• NQO1
• T type calcium channel
• Synaptic transmission
Scope of the Epilepsy Pipeline Report
- Coverage: Global
- Major Players: Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
- Key Epilepsy Pipeline Therapies: OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others.
Dive deep into rich insights of Epilepsy novel and emerging drugs and their analysis @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight
Table of Contents
1 Introduction
2 Executive Summary
3 Epilepsy Overview
4 Epilepsy – Analytical Perspective In-depth Commercial Assessment
5 Epilepsy Pipeline Therapeutics
6 Late Stage Epilepsy Products (Phase III)
7 Late Stage Epilepsy Products (Phase II/III)
8 Mid Stage Epilepsy Products (Phase II)
9 Early Stage Epilepsy Products (Phase I)
10 Epilepsy therapeutic Assessment
11 Inactive Epilepsy Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Epilepsy Key Companies
14 Epilepsy Key Products
15 Epilepsy Unmet Needs
16 Epilepsy Market Drivers and Barriers
17 Epilepsy Future Perspectives and Conclusion
18 Epilepsy Analyst Views
19 Appendix
20 About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting